Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
Rhea-AI Summary
Avantor (NYSE: AVTR) appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) and Chief Transformation Officer, effective May 1, 2026. He will lead BMP growth, improve operational performance, and head the Revival Management Office to drive enterprise transformation. Benoit Gourdier will remain through end of 2026 to transition the role.
Positive
- Start date: May 1, 2026 for new EVP and Chief Transformation Officer
- Brings operational experience from Cytiva/Danaher including hardware and integrated solutions
- Will lead the Revival Management Office to drive enterprise transformation
- Planned overlap: current BMP leader stays until end of 2026 to ensure transition
Negative
- Transition period extends through end of 2026, creating temporary leadership overlap
- Potential execution risk while implementing broad transformation initiatives across the enterprise
News Market Reaction – AVTR
In the Apr 24 session, AVTR gained 1.80%, reflecting a mild positive market reaction. Argus tracked a trough of -5.9% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | Product portfolio update | Positive | +0.3% | Unification of Masterflex fluid handling portfolio across bioprocess workflows. |
| Apr 13 | Facility expansion | Positive | +3.5% | Expansion of St. Louis site with new microbial and stability testing. |
| Apr 01 | CFO transition | Neutral | -0.9% | Planned CFO departure with interim CFO appointed and 2026 guidance reaffirmed. |
| Feb 11 | Earnings and turnaround | Negative | -13.6% | 2025 results with sales decline, GAAP net loss, and Revival program outline. |
| Jan 15 | Dividend declaration | Positive | +1.2% | IVR monthly dividend and leverage/book value update, unrelated to Avantor. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Avantor news—product portfolio moves, facility expansion, and leadership changes—has usually seen price moves that align directionally with the perceived tone of the announcements, with the turnaround-focused earnings update coinciding with the sharpest decline.
Over the past few months, Avantor has reported several operational and leadership developments. On Apr 21, it unified the Masterflex fluid handling portfolio across R&D to bioprocess manufacturing. On Apr 13, it expanded a St. Louis facility with GMP-aligned microbial testing to support 2,000+ samples annually. On Apr 1, it announced a CFO transition while reaffirming 2026 guidance. The Feb 11 earnings release detailed $6.55B 2025 sales and the “Revival” program. Today’s appointment of a BMP and transformation leader fits into this broader Revival and leadership-refresh narrative.
Key Terms
bioprocessing medical
biopharma medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
In this role, Mr. Brellier will be responsible for growing the BMP business and improving operational performance. He will also lead the Revival Management Office, driving transformation initiatives across the enterprise.
Mr. Brellier is an accomplished executive with deep operational experience across healthcare and strategic business transformation. He joins Avantor from Danaher, where he was most recently President of Cytiva's Hardware Solutions business, leading five business units responsible for early innovation through manufacturing and commercialization of services for the biopharma industry. While at Cytiva, Mr. Brellier previously served as President of Integrated Solutions & Services and VP Business Operations. He also led the effort to establish Cytiva as a standalone operating company within Danaher as well as the integration of Pall Life Sciences and Cytiva.
"Ludovic is a skilled operator who has a successful track record of growing bioprocessing businesses both organically and inorganically, and our BMP segment is a strong platform that has a lot of potential for growth under his leadership," said Emmanuel Ligner, Avantor's President and CEO. "As we execute Revival across our enterprise, Ludovic's past transformation and integration experience will be critical." Ligner concluded.
Mr. Brellier added, "Avantor's bioprocessing platform has leading product brands with rich legacies and strong customer preference. I look forward to leveraging my manufacturing and commercialization skills to enhance our operations and drive sustainable growth in the business by enabling the product brands to reach their full potential. The successful execution of Revival will be critical to the success of both Avantor's business segments," Brellier concluded.
Benoit Gourdier, current Executive Vice President of Avantor's BMP Segment, will stay with the company until on or before the end of 2026 to ensure a smooth transition.
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
Investor Relations Contact
Chris Fidyk
Vice President, Investor Relations
Avantor
Chris.Fidyk@avantorsciences.com
Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-announces-ludovic-brellier-as-executive-vice-president-bioscience--medtech-products-bmp--chief-transformation-officer-302752230.html
SOURCE Avantor and Financial News